Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Answer from: at Academic Institution
My practice has been that after 2-3 years of denosumab, I wait 6 months and then start zoledronic acid.
Sign in or Register to read more
Answer from: at Community Practice
Six months after the last injection.
Sign in or Register to read more
Answer from: at Community Practice
Yes, 6 months after last Prolia shot. I give 2 doses of Zoledronic 1 year apart and then consider drug holiday based on the DEXA report.
Sign in or Register to read more
24261
24290
25967
Related Questions
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
Would you consider PTH analogue in a patient with mildly elevated PTH?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?